Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects.
OBJECTIVE
Susceptibility to neuroleptic-induced extrapyramidal syndromes varies widely, even within age and sex subgroups. Individual vulnerability to extrapyramidal syndromes has been assumed to explain this, but the utility of past history for predicting future occurrence of extrapyramidal syndromes has not been studied extensively. This investigation was undertaken to determine whether patients' previous histories of extrapyramidal syndromes predict future episodes of extrapyramidal syndromes and to compare the importance of this predictive factor with patient age, sex, neuroleptic dose, and anticholinergic dose as predictors of extrapyramidal syndromes.


METHODS
The charts of 62 schizophrenic patients with multiple neuroleptic treatment episodes were reviewed. Extrapyramidal syndromes, neuroleptic drug doses, and anticholinergic drug doses during the first 21 days of each treatment episode were recorded.


RESULTS
Previous extrapyramidal syndromes correctly predicted extrapyramidal syndromes in subsequent treatments for 84% of the patients. Variations in neuroleptic potency, neuroleptic dose, and anticholinergic dose partially explained incorrect predictions.


CONCLUSIONS
These results support the hypothesis that patients with a history of extrapyramidal syndromes are at greater risk for future extrapyramidal syndromes. If confirmed, these results strongly support individual susceptibility as a major predictor of extrapyramidal syndromes and indicate that prophylaxis of extrapyramidal syndromes should be considered for patients who have previously suffered extrapyramidal syndromes from similarly prescribed neuroleptic therapy.
Keepers
G A
GA
Inpatient Psychiatry Section, Portland VA Medical Center, OR 97207.
Casey
D E
DE
D000328:Adult; D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D001590:Benztropine / Q000627:therapeutic use; D002746:Chlorpromazine / Q000009:adverse effects; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D008297:Male; D008499:Medical Records; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D011336:Probability; D012008:Recurrence; D012307:Risk Factors; D012737:Sex Factors
D014150:Antipsychotic Agents; D001590:Benztropine; D002746:Chlorpromazine